Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Pharmacology of Ion Channels and Channelopathies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1674861

Integrating drug effects on individual cardiac ionic currents and cardiac action potentials to understand nonclinical translation to clinical ECG changes

Provisionally accepted
Lars  JohannesenLars Johannesen1*Najah  Abi-GergesNajah Abi-Gerges2Katrina  SweatKatrina Sweat2Ana  RoupAna Roup2Guy  PageGuy Page2Claudia  Alvarez BaronClaudia Alvarez Baron1Huimei  YuHuimei Yu1Wendy  W WuWendy W Wu1*
  • 1United States Food and Drug Administration, Silver Spring, United States
  • 2AnaBios Corporation, San Diego, United States

The final, formatted version of the article will be published soon.

Concomitant inhibition of the late Na+ current (INaL) and/or the L-type Ca2+ current (ICaL) has been hypothesized to mitigate hERG block-mediated QTC prolongation. This hypothesis was tested in a clinical trial using drugs selected based on available patch clamp data at the time. The results showed that hERG block-mediated QTC prolongation with dofetilide was shortened by co-administration of lidocaine or mexiletine – drugs that inhibit INaL. However, diltiazem, selected as the preferential ICaL inhibitor, did not shorten hERG block-mediated QTC prolongation by moxifloxacin. Patch clamp results can be sensitive to experimental differences across laboratories. Therefore, this study reexamined the effects of all drugs on INaL, ICaL, and hERG current using overexpression cell lines and physiologically relevant experimental protocols aimed at producing drug-channel interaction characteristics in humans. Drug effects on ventricular action potentials (APs) from adult human trabeculae were also tested to better understand the nonclinical and clinical findings. Mexiletine and lidocaine showed similar potencies on inhibiting INaL and ICaL in the prior and present patch clamp studies. Both drugs reduced dofetilide-induced AP duration (APD) prolongation, consistent with the clinical data. For diltiazem, the ICaL potency and the separation between ICaL and hERG potencies (ICaL: 1.3 µM; hERG: 8.9 µM; hERG-to-ICaL ratio = 7) is much reduced comparing to the prior results (ICaL: 112.1 nM; hERG: 6.6 µM; ratio = 59). These new findings are consistent with diltiazem-induced APD shortening and AP triangulation caused by greater reductions in the early rather than late repolarization – a signature of multi-ion channel block. Consistent with this interpretation, nifedipine, which preferentially inhibits ICaL over hERG (ICaL: 13.2 nM; hERG: 35 µM; ratio = 2651) caused APD shortening without AP triangulation. Results from this study thus support the following: 1) diltiazem failed to reduce moxifloxacin-induced QTC prolongation due to its concomitant hERG block at clinical exposure levels; and 2) the importance of using physiologically relevant protocols to generate ion channel pharmacology and obtaining functional recordings from myocytes to provide a better understanding of nonclinical data translation to clinical ECG signals. Data used in this manuscript, including the original electrophysiology records, may be found at: https://osf.io/69ght/. 

Keywords: hERG, torsade, QT prolongation, Nav1.5, CaV1.2, Cardiac safety, human ventricular myocytes, Multi-ion channel block

Received: 05 Aug 2025; Accepted: 22 Oct 2025.

Copyright: © 2025 Johannesen, Abi-Gerges, Sweat, Roup, Page, Baron, Yu and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Lars Johannesen, lars.johannesen@fda.hhs.gov
Wendy W Wu, wendy.wu@fda.hhs.gov

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.